FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2019/02/017623 [Registered on: 12/02/2019] Trial Registered Prospectively
Last Modified On: 08/01/2020
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Single Arm Study 
Public Title of Study   Developing an efficient and cost effective method for screening of oral cancer in India 
Scientific Title of Study   A pilot study to develop an efficacious oral cancer screening strategy for India 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Kunal Oswal 
Designation  Research Manager 
Affiliation  Tata Trusts 
Address  Room No.-184A, 18th Floor, Maker Building E-wing, Cuffe Parade, Mumbai Department- Research Division- Cancer Program
G-14, Raval Chambers, Aai Mai Merwanji lane, Parel, Mumbai-12
Mumbai
MAHARASHTRA
400 005
India 
Phone  9930011149  
Fax    
Email  koswal@tatatrusts.org  
 
Details of Contact Person
Scientific Query
 
Name  Umakant Nadkar 
Designation  Research Manager 
Affiliation  Tata Trusts 
Address  Room No- 184A, 18th Floor, Maker Building E-wing, Cuffe Parade, Mumbai Department- Research Division- Cancer Program
14, Krishna Ganga, Nandivili Tekdi, Dombivili East-421201
Thane
MAHARASHTRA
400 005
India 
Phone  9892352563  
Fax    
Email  umakant@tatatrusts.org  
 
Details of Contact Person
Public Query
 
Name  Rishav Kanodia 
Designation  Research Manager 
Affiliation  Tata Trusts 
Address  Room No.- 184A, 18th Floor, Maker Building E-wing, Cuffe Parade, Mumbai Department- Research Division- Cancer Program

Mumbai
MAHARASHTRA
400 005
India 
Phone  9920188546  
Fax    
Email  rkanodia@tatatrusts.org  
 
Source of Monetary or Material Support  
Medical Research Council (MRC), 14th floor One Kemble Street London WC2B 4AN, UK 
Tata Trusts, 184A, Maker Building E, Cuffe Parade, Mumbai- 400005 
 
Primary Sponsor  
Name  Tata Trusts 
Address  184B, Maker Building E, Captain Prakash Pethe Marg, Cuffe Parade, Mumbai, Maharashtra 400005  
Type of Sponsor  Other [Public Trust] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr S M Bhagabaty  Dr. B. Borooah Cancer Institute  Department of Preventive Oncology, BBCI, AK Azad Road, Gopinath Nagar Rd, Bishnu Rabha Nagar, Guwahati, Assam 781016
Kamrup
ASSAM 
9435301579

srabana.misra@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Dr. B. Borooah Cancer Institute  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  Screening for Oral cancer 
 
Intervention / Comparator Agent  
Type  Name  Details 
 
Inclusion Criteria  
Age From  30.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  All healthy individuals aged between 30 to 65 years, with exposure to tobacco,
areca nut and alcohol, will be included in the study.  
 
ExclusionCriteria 
Details  No exclusions, except based on age and tobacco use.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
a.Develop an effective risk prediction model for identifying high-risk individuals
b. To develop a high sensitivity, specificity, high negative reassurance for screen individuals, high positive predictive value for screen positive screening strategy using COE and autofluorescence, with biopsy/histopathology as the gold-standard.
 
a. Development of Risk prediction model- End of year 1
2. Validation of the risk-prediction model- End of year 2 
 
Secondary Outcome  
Outcome  TimePoints 
Asses the utility of risk prediction, cytology, and somatic molecular markers for selection of individuals for screening and triage of individuals for biopsy.  End of year 2 
 
Target Sample Size   Total Sample Size="30000"
Sample Size from India="30000" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/03/2019 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Open to Recruitment 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   All partners will be collectively publish research articles based on the study after the end of the screening trial 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

Oral cancer imposes a huge burden globally, especially in low and middle income countries (LMICs). This high burden of oral cancer is attributable to high prevalence of risk factors such as tobacco, areca nut (tamul) and alcohol. In most countries, cigarette smoking is the predominant form of tobacco use. However, in India, approximately 75% of tobacco consumption is in smokeless form. India has the highest burden of oral cancer globally. It is recognized that smokeless tobacco causes cancers of the mouth, gullet and pancreas. The proposed study will be conducted in Assam, where the prevalence of tobacco is 48%. In Assam, tamul is traditionally offered as a mark of respect and auspicious beginnings. We recently conducted a survey in Assam on tamul use. In all, 34% of subjects reported using tamul. Influencing factors were family (58%) and friends (34%). Majority of the subjects (60%) chewed tamul due to pressure at work, after food and during leisure with a mean age of initiation at 15 years. While knowledge about the ill-effects of tamul was low and willingness to quit high (77%), paradoxically, 81% of subjects had not attempted to quit the habit in the preceding 6 months.

The 5-year survival rate for oral cancer is 80% in those diagnosed at early stage and only 20% in those diagnosed at advanced stage, underscoring the need for early detection. In India, most oral cancer patients present with advanced disease and have survival rates as low as 3-5%. There is, therefore, a pressing need to diagnose early and ideally at a precancerous stage. In India and other LMICs, the current approach for oral cancer screening relies on visual inspection of the inner lining of the oral cavity (conventional oral examination [COE]) in tobacco/ alcohol users aged over 30 years. Yet, owing to issues with the method of screening (low sensitivity of COE) and size of the target population (ages 30+), this approach is not efficacious. For example, the eligible population for oral cancer screening in India based on COE is ~300 million, which reduces its operational feasibility and makes it cost prohibitive. Any screening system developed in LMICs should fulfill two features for optimal effectiveness: 1) The screening test should have high accuracy 2) The screening system (infrastructure, human resource and referral centres) has to be financially viable. Unfortunately, the current oral cancer screening strategy of visual inspection in India and several other LMICs fails at both these levels. Risk stratification tools for systematic identification of high-risk population could potentially drastically reduce the target population for screening. 

We propose a 3-step oral cancer screening strategy to enable effective implementation of the screening program. First, a risk prediction model will be used for identification of those at greatest risk of oral cancer, thus reducing the number of screened individuals and enhancing cost effectiveness. Second, high-risk individuals will be screened using autoflourescence, a highly sensitive test for diagnosing oral cancer to rule-out disease by causing only the abnormal areas to light up. Finally, individuals positive on autofluorescence will be ruled-in through a brush biopsy to look for suspicious cells, a test that is highly specific for diagnosing oral cancer. We will validate the risk prediction model of the proposed 3-step strategy as part of this pump priming application which will subsequently lead to a large randomized controlled trial in the population of North East India to test its effectiveness. Our study will provide proof-of-principle of the 3-step screening strategy for implementation of the oral cancer screening in LMICs.

 
Close